Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management.

about

Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management.

Item

http://www.wikidata.org/entity/Q55420352

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Safety and Efficacy of Extreme ...... in Hyperlipidemia Management.

@en

Safety and Efficacy of Extreme ...... in Hyperlipidemia Management.

@nl

type

Item

label

Safety and Efficacy of Extreme ...... in Hyperlipidemia Management.

@en

Safety and Efficacy of Extreme ...... in Hyperlipidemia Management.

@nl

prefLabel

Safety and Efficacy of Extreme ...... in Hyperlipidemia Management.

@en

Safety and Efficacy of Extreme ...... in Hyperlipidemia Management.

@nl

P1476

Safety and Efficacy of Extreme ...... in Hyperlipidemia Management.

@en

P2093

Arshna Qureshi

http://www.w3.org/2001/XMLSchema#string

Kumar Ashish

http://www.w3.org/2001/XMLSchema#string

Lyndsey R Heise

http://www.w3.org/2001/XMLSchema#string

Raktim K Ghosh

http://www.w3.org/2001/XMLSchema#string

Sudeshna Ghosh

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.

Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.

Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.

Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer.

Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management

P304

8598054

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2018/8598054

http://www.w3.org/2001/XMLSchema#string

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Dhrubajyoti Bandyopadhyay

Adrija Hajra

P577

2018-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29850255

http://www.w3.org/2001/XMLSchema#string

P921

hyperlipidemia

P932

5937425

http://www.w3.org/2001/XMLSchema#string